John Jacob Orloff
Independent DirectorDr. John Jacob Orloff, M. D., serves as Venture Partner at Agent Capital, LLC since joining in October 2021. Dr. Orloff is Independent Director of Zenas BioPharma, Inc. (also known as Zenas BioPharma (Cayman) Limited) and served as its Director since January 2022. He had been an Executive Vice President and Global Head of Research & Development at Alexion Pharmaceuticals, Inc. since June 05, 2017. He served as a Independent Non-Executive Director at BenevolentAI société since April 2022 until October 17, 2024 and Workforce Non-Executive Director since March 2023 until October 17, 2024. He focused on strengthening the Alexions clinical pipeline and research programs, enhancing R&D productivity, overseeing regulatory and medical affairs and supporting business development. He joined the Alexion Pharmaceuticals, Inc. in June 2017. He experiences in successfully developing biopharmaceuticals, including in the areas of hematology, immunology and metabolics, as well his strong global clinical and regulatory expertise, makes him ideally suited to lead the R&D function at Alexion. He is Director at Zenas BioPharma Limited since January 2022. He has been Executive Vice President and Head of Research & Development at Aegerion Pharmaceuticals, Inc. since November 3, 2016. In this role, he oversees the effort to build a nimble development organization to advance its portfolio of products for rare diseases, including the design of a clinical program for MYALEPT with the goal of developing it to its full potential. He served as Head of Research & Development and Executive Vice President of Novelion Therapeutics Inc. since November 2016 until May 2017. He has many years of global experience in industry, clinical, drug discovery and development. From July 2015 to July 2016, he served as Chief Scientific Officer, Global Head of Research & Development and Executive Vice President at Baxalta Incorporated, where he advanced its pipeline and oversaw regulatory approval of 10 unique products and two devices over two years. He is a global R&D business leader with experience in the biopharmaceutical industry and deep expertise spanning various stages of clinical and non-clinical development, including developing medicines for rare diseases. He was responsible for advancing Baxalta's pipeline across hematology, immunology and oncology. He served as Global Head of Research & Development and Vice President at Baxter BioScience Inc., since joining in July 2014. He was responsible for advancing the late-stage BioScience pipeline, enhancing the R&D operating model and additional innovative opportunities for the business. He served as Vice President for Clinical Development and Medical Affairs at the Novartis business franchise for Arthritis, Bone and Women?s Health of Novartis AG. He served as Global Head of Clinical Development and Senior Vice President at Merck Serono Pharmaceuticals. From 2003 to 2013, he held a series of scientific leadership roles at Novartis Pharma AG. He also held executive R&D roles with Baxter International from July 2014 to June 2015, Merck Serono from January 2014 to May 2014, Novartis from April 2003 to October 2013 and Merck Research Laboratories. He served as Chief Medical Officer and Senior Vice President of Global Development for Novartis Pharma AG where he led the Trials of the Future initiative to get innovation to the drug development process. He also served as Head of U. S. Medical and Drug Regulatory Affairs for North America. He was a senior Director at Merck Research Laboratories, where he began as an associate Director in 1997. He supported clinical development at Merck Research Labs and was previously a faculty Member at the Yale University School of Medicine for seven years. His expertise in bone biology contributed to marketing approvals for treatments for a range of bone disorders and he has led programs across a diverse range of therapeutic areas, including immunology, neurology and oncology. Prior to joining the biopharmaceutical industry in 1997, he was with the Yale School of Medicine for seven years. He served as Director of Novelion Therapeutics Inc. from July 01, 2017 to September 24, 2019. He is a Director at Novelion. He served as Member of Innovation Advisory Board at Mytrus, Inc., since March 18, 2014. He completed his internal medicine residency at University of Pittsburgh Medical Center and his endocrinology and metabolism fellowship at Yale University School of Medicine. He holds an M. D. from University of Vermont College of Medicine and a B. A. in chemistry from Dartmouth College.
Positions
- Company NameZenas BioPharma, Inc.Stock CodeZBIOPositionIndependent DirectorColleagues
- LOLeon Oliver MoulderFounder, CEO & Chairman
- JLJoseph L. FarmerCOO, President, Principal Financial Officer & Principal Accounting Officer
- LVLisa von MoltkeHead of Research & Development and Chief Medical Officer
- HSHeinrich SchliekerChief Technical Officer
- HLHaley LakenChief Scientific Officer
- PLPatricia L. AllenIndependent Director
- JRJason Raleigh NunnIndependent Director
- JPJames Patrick BoylanLead Independent Director
